Nunn PA - Search Results

1

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.

Langrish CL, Bradshaw JM, Francesco MR, Owens TD, Xing Y, Shu J, LaStant J, Bisconte A, Outerbridge C, White SD, Hill RJ, Brameld KA, Goldstein DM, Nunn PA. Langrish CL, et al. Among authors: nunn pa. J Immunol. 2021 Apr 1;206(7):1454-1468. doi: 10.4049/jimmunol.2001130. Epub 2021 Mar 5. J Immunol. 2021. PMID: 33674445 Free PMC article.

2

Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus.

Goodale EC, Varjonen KE, Outerbridge CA, Bizikova P, Borjesson D, Murrell DF, Bisconte A, Francesco M, Hill RJ, Masjedizadeh M, Nunn P, Gourlay SG, White SD. Goodale EC, et al. Vet Dermatol. 2020 Aug;31(4):291-e71. doi: 10.1111/vde.12841. Epub 2020 Mar 4. Vet Dermatol. 2020. PMID: 31899567

3

Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus.

Goodale EC, White SD, Bizikova P, Borjesson D, Murrell DF, Bisconte A, Francesco M, Hill RJ, Masjedizadeh M, Nunn P, Gourlay SG, Jordan TJM, Emery CB, Outerbridge CA. Goodale EC, et al. Vet Dermatol. 2020 Oct;31(5):410-e110. doi: 10.1111/vde.12878. Epub 2020 Aug 17. Vet Dermatol. 2020. PMID: 32803903 Free PMC article.

4

Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models.

Xing Y, Chu KA, Wadhwa J, Chen W, Zhu J, Bradshaw JM, Shu J, Foulke MC, Loewenstein N, Nunn P, By K, Phiasivongsa P, Goldstein DM, Langrish CL. Xing Y, et al. Immunohorizons. 2021 Jul 29;5(7):581-589. doi: 10.4049/immunohorizons.2100063. Immunohorizons. 2021. PMID: 34326199 Free article.

5

Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).

Owens TD, Brameld KA, Verner EJ, Ton T, Li X, Zhu J, Masjedizadeh MR, Bradshaw JM, Hill RJ, Tam D, Bisconte A, Kim EO, Francesco M, Xing Y, Shu J, Karr D, LaStant J, Finkle D, Loewenstein N, Haberstock-Debic H, Taylor MJ, Nunn P, Langrish CL, Goldstein DM. Owens TD, et al. J Med Chem. 2022 Apr 14;65(7):5300-5316. doi: 10.1021/acs.jmedchem.1c01170. Epub 2022 Mar 18. J Med Chem. 2022. PMID: 35302767

6

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168).

Owens TD, Smith PF, Redfern A, Xing Y, Shu J, Karr DE, Hartmann S, Francesco MR, Langrish CL, Nunn PA, Gourlay SG. Owens TD, et al. Among authors: nunn pa. Clin Transl Sci. 2022 Feb;15(2):442-450. doi: 10.1111/cts.13162. Epub 2021 Nov 12. Clin Transl Sci. 2022. PMID: 34724345 Free PMC article. Clinical Trial.

7

Prolonged and tunable residence time using reversible covalent kinase inhibitors.

Bradshaw JM, McFarland JM, Paavilainen VO, Bisconte A, Tam D, Phan VT, Romanov S, Finkle D, Shu J, Patel V, Ton T, Li X, Loughhead DG, Nunn PA, Karr DE, Gerritsen ME, Funk JO, Owens TD, Verner E, Brameld KA, Hill RJ, Goldstein DM, Taunton J. Bradshaw JM, et al. Among authors: nunn pa. Nat Chem Biol. 2015 Jul;11(7):525-31. doi: 10.1038/nchembio.1817. Epub 2015 May 25. Nat Chem Biol. 2015. PMID: 26006010 Free PMC article.

8

A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects.

Ucpinar S, Darpo B, Neale A, Nunn P, Shu J, Chu KA, Kavanagh M, Xue H, Phiasivongsa P, Thomas D, Smith PF. Ucpinar S, et al. Clin Transl Sci. 2022 Jun;15(6):1507-1518. doi: 10.1111/cts.13271. Epub 2022 Apr 3. Clin Transl Sci. 2022. PMID: 35301810 Free PMC article. Clinical Trial.

9

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.

Smith PF, Krishnarajah J, Nunn PA, Hill RJ, Karr D, Tam D, Masjedizadeh M, Funk JO, Gourlay SG. Smith PF, et al. Among authors: nunn pa. Br J Clin Pharmacol. 2017 Nov;83(11):2367-2376. doi: 10.1111/bcp.13351. Epub 2017 Aug 1. Br J Clin Pharmacol. 2017. PMID: 28636208 Free PMC article. Clinical Trial.

10

Characterization of a novel CRAC inhibitor that potently blocks human T cell activation and effector functions.

Chen G, Panicker S, Lau KY, Apparsundaram S, Patel VA, Chen SL, Soto R, Jung JK, Ravindran P, Okuhara D, Bohnert G, Che Q, Rao PE, Allard JD, Badi L, Bitter HM, Nunn PA, Narula SK, DeMartino JA. Chen G, et al. Among authors: nunn pa. Mol Immunol. 2013 Jul;54(3-4):355-67. doi: 10.1016/j.molimm.2012.12.011. Epub 2013 Jan 26. Mol Immunol. 2013. PMID: 23357789

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters